18 May 2013
Keywords: over, patients, enrolled, generex, oral-lyn, trial, usa-based
Article | 22 September 2008
USA-based Generex Biotechnology has reached an enrollment milestone in its pivotal Phase III study of Oral-Lyn prandial oral insulin spray.
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
22 September 2008
17 May 2013
© 2013 thepharmaletter.com